Literature DB >> 11916571

Toxicoproteomics -- a new preclinical tool.

Lasantha R Bandara1, Sandy Kennedy.   

Abstract

The publication of the human genome has presented the scientific community with an unprecedented amount of genetic information with the potential to revolutionize the drug discovery process. This information could be used to identify novel drug targets and disease markers or could aid in the development of personalized medicines. The realization that genetic changes must ultimately influence protein function has pushed the field of proteomics further into the limelight. In this review the applications of proteomics to the field of toxicology will be discussed. It is anticipated that, in the future, toxicologists will apply a range of genomic and proteomic techniques to address issues in toxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916571     DOI: 10.1016/s1359-6446(02)02211-0

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  6 in total

Review 1.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  In vitro transcriptomic prediction of hepatotoxicity for early drug discovery.

Authors:  Feng Cheng; Dan Theodorescu; Ira G Schulman; Jae K Lee
Journal:  J Theor Biol       Date:  2011-08-27       Impact factor: 2.691

3.  Identification of EBP50 as a specific biomarker for carcinogens via the analysis of mouse lymphoma cellular proteome.

Authors:  Yoen Jung Lee; In-Kwon Choi; Yhun Yhong Sheen; Sue Nie Park; Ho Jeong Kwon
Journal:  Mol Cells       Date:  2012-02-28       Impact factor: 5.034

4.  Moesin is a biomarker for the assessment of genotoxic carcinogens in mouse lymphoma.

Authors:  Yoen Jung Lee; In-Kwon Choi; Yhun Yhong Sheen; Sue Nie Park; Ho Jeong Kwon
Journal:  Mol Cells       Date:  2012-01-26       Impact factor: 5.034

Review 5.  The role of toxicoproteomics in assessing organ specific toxicity.

Authors:  B Alex Merrick; Frank A Witzmann
Journal:  EXS       Date:  2009

Review 6.  Mass casualties and health care following the release of toxic chemicals or radioactive material--contribution of modern biotechnology.

Authors:  Ann Göransson Nyberg; Daniela Stricklin; Åke Sellström
Journal:  Int J Environ Res Public Health       Date:  2011-12-07       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.